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Abstract: This narrative review highlights routes of ocular drug delivery for age-related macular
degeneration (AMD). AMD is the leading cause of irreversible blindness in industrialized countries and
accounts for 8.7% of blindness worldwide. Advanced AMD can be classified into two subtypes: late-stage dry
AMD [known as geographic atrophy (GA)] and neovascular AMD (nAMD). GA is often bilateral and results
from progressive and irreversible loss of photoreceptors and areas of the retinal pigment epithelium. Wet
AMD is characterized by angiogenesis from the choroid to the normally avascular regions underneath the
retinal pigment epithelium (RPE) or retina, a process known as choroidal neovascularization (CNV). Various
targeted therapeutic options are currently available to reduce the progression rate and maintain vision in
patients with nAMD. Intravitreal delivery of anti-VEGF protein treatments to halt CNV is currently the
gold-standard of care for nAMD. Subretinal and suprachoroidal delivery approaches are also being explored
for gene and molecular therapies. Advancements in nanotechnology and biomaterials have also led to the
development of microscopic drug delivery systems, including hydrogels, microparticles, nanoparticles,
implants, and liposomes. Gene therapy and stem cell therapy has recently emerged as a potential candidate
treatment modality for AMD and other retinal degenerations. New drug targets and modalities have
stimulated exciting developments in ocular drug delivery with the promise of greater efficacy and durability
of AMD treatment.
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Introduction
Age-related macular degeneration (AMD), a progressive
disease affecting the central retina, is the leading cause
of irreversible blindness in industrialized countries and
accounts for 8.7% of blindness worldwide (1). Age is the
leading risk factor for development of AMD, affecting
4.8% of people ages 65 and older, and up to 25% of people
by age 80 (2,3). In the early stages of AMD (also known
as “dry” AMD), the clinical presentation can range from
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asymptomatic to blurred central vision that impairs daily
activities. It is pathologically characterized by thickening
of Bruch’s membrane due to yellow, subretinal deposits
of lipid-rich proteins called drusen (4,5). The buildup of
drusen disrupts both fluid efflux across Bruch’s membrane
and cholesterol metabolism, causing oxidative stress on the
RPE and accumulation of lipid peroxidation byproducts
(6,7). Dry AMD can remain stable and minimally
symptomatic for many years. However, 20.2% of cases
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progress to advanced disease which contributes to 90% of
AMD-related blindness (8-10).
Advanced AMD can be classified into two subtypes:
late-stage dry AMD [known as geographic atrophy (GA)],
and neovascular (“wet”) AMD (nAMD). GA results
from progressive, irreversible loss of photoreceptor and
retinal pigment epithelium (RPE) cells by the mechanism
described above (11). Wet AMD is believed to arise from
abnormal blood vessel growth from the choroid into the
normally avascular subretinal and sub-RPE layers, a process
known as choroidal neovascularization (CNV) (3,5). CNV
is thought to be a multifactorial consequence of drusen
accumulation, disrupted choroidal blood supply to the
RPE, and hypoxic conditions that induce the expression of
angiogenic signaling proteins (5). If untreated, nAMD can
lead to retinal exudation, sub-macular hemorrhage, and
subretinal fibrosis that significantly impairs vision.
The treatment of nAMD has significantly advanced
since the era of thermal laser photocoagulation and
photodynamic therapy (PDT) two to three decades ago (12).
Currently, intravitreal anti-vascular endothelial growth
factor (VEGF) injection is the gold-standard therapy that
can maintain or improve visual acuity in the majority of
patients with nAMD. However, to date, no treatment exists
for progression of dry AMD or GA (13).
This literature review aims to highlight standard-ofcare and clinical trial evaluation of drug delivery routes for
the treatment of wet AMD, and therapies currently being
evaluated for both neovascular and non-neovascular AMD
(Figures 1,2). Numerous drug targets and therapeutic routes
are currently being explored and exciting advances are
currently under clinical investigation (14-17). The goal of
our review is to summarize therapies that are currently in
clinical use, therapies under investigation in clinical trials, and
therapeutics that did not meet their clinical trial endpoint.
The review was conducted using Pubmed to identify
peer-reviewed journal articles using the keywords agerelated macular degeneration, anti-vascular endothelial
growth factor, ocular gene therapy, and other related search
terms between the years of 1990 to 2020. ClinicalTrials.
gov was used to gather data on current clinical trials not yet
published in the literature. We present the following article
in accordance with the Narrative Review reporting checklist
(available at http://dx.doi.org/10.21037/aes-21-8).
Intravitreal therapies
Intravitreal injection (IVI) of anti-VEGF agents is currently
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the standard of care for nAMD (18). This delivery route has
become well-established in vitreoretinal practices and is safe
and efficacious. IVI is a simple, minimally-invasive delivery
method that is used to provide efficient, in-office treatment.
Topical anesthesia is sufficient for the majority of patients,
though subconjunctival anesthetic can also be administered.
A 30-gauge needle (or smaller) is typically used to
administer 0.05cc of drug, although up to 0.1cc of fluid can
be safely tolerated during IVI with minimal transient rise in
intraocular pressure (19,20).
Despite their efficacy, IVIs still carry a risk for visuallysignificant complications that increases with the number of
injections (21). Risks include endophthalmitis, intraocular
inflammation, rhegmatogenous retinal detachment (RRD),
and IOP elevation (22-24). Not only do these complications
increase with the number of injections, but the four to eight
week anti-VEGF injection schedule typically required to
control exudation poses a significant treatment burden
on the patient, provider, and entire healthcare system.
Consequently, the frequency of injections administered
in clinical trials is often greater than the frequency in
real-world clinical practice. Additionally, the course of
disease is variable between patients, and those with greater
neovascular activity or bilateral disease may require more
frequent visits which may lead to treatment fatigue.
These burdens, in part, account for the discrepancy in
visual outcomes of nAMD patients between clinical trials
versus observational studies, with the former showing a 1
to 2 letter-line improvement (25-29) and the latter only
approximately 1 letter-line improvement (30-34).
Steroid therapies
Intravitreal corticosteroids are commonly used as a
standalone therapy for various retinal diseases, including
diabetic macular edema (DME), cystoid macular edema
(CME), uveitis, and retinal vascular occlusion (RVO) (35).
Steroids induce the production of various proteins that
inhibit the release of arachidonic acid, a critical player in
the expression of pro-inflammatory markers, from cellular
plasma membranes (35,36). Among many cellular growth
factors that have been isolated in ocular neovascularization,
VEGF has been shown to play a key role in the pathogenesis
of nAMD (8,37). Steroids lead to downstream inhibition of
VEGF expression and decreased blood vessel permeability,
and were thus thought to have therapeutic potential for
treatment of nAMD. However, studies have failed to show
steroid monotherapy to be beneficial, and it is therefore,

Ann Eye Sci 2021;6:33 | https://dx.doi.org/10.21037/aes-21-8

Annals of Eye Science, 2021

Page 3 of 20
Dexamethasone implant
in conjunction with
anti-VEGF therapy

Steroids

Intravitreal
therapies
Anti-VEGF
agents

Triple therapy
(dexamethasone,
photodynamic therapy,
bevacizumab)

Bevacizumab
(Avastin, Lytenava)

full-length, humanized
anti-VEGF-A monoclonal
IgG1 antibody

Pegaptanib (Macugen)

anti-VEGF RNA aptamer
that selectively binds
VEGF-165

Ranibizumab (Lucentis)

humanized anti-VEGF-A
antibody fragment

Aflicbercept (Eylea)

Subretinal
therapies

Brolucizimab (Beovu)

humanized, single-chain
variable fragment that
binds VEGF-A

Anti-VEGF
gene therapy

ADVM-022

AAV2 capsid that delivers
cDNA encoding aflibercept
protein

Anti-VEGF
gene therapy

RGX-314

AAV8 vector that delivers
soluble anti-VEGF Fab
protein

RGX-314

AAV8 vector that delivers
soluble anti-VEGF Fab
protein

OTX-AFS

extended-release
suprachoroidal formulation
of aflibercept

CLS-AX

injectable suspension of
axitinib, a tyrosine kinase
inhibitor (TKI) that disrupts
VEGF signaling

Port Delivery
System (PDS)

Ranibizumab PDS

humanized anti-VEGF-A
antibody fragment

Hydrogels

OTX-TKI

Treatments for
wet AMD
Suprachoroidal
therapies

Nanotechnology
and Drug Delivery
Systems

chimeric fusion protein that
binds all isoforms of VEGF-A,
plus VEGF-B and PIGF

Anti-VEGF
gene therapy

Bevasirinib

anti-angiogenic siRNA
therapeutic designed to
silence the VEGF gene

AGN211745

anti-angiogenic siRNA that
utilized RNAi technology to
target VEGFR-1 in patients
with CNV

Abicipar pegol

high-affinity VEGF-A binder

Small-interfering
RNA (siRNA)

Designed Ankyrin
repeat proteins

X-82

Oral anti-VEGF/PDGF
formulation

AREDS2

Vitamins (C and E),
carotenoids (lutein and
zeaxanthin), and minerals
(zinc and copper)

Oral Therapies

biodegradable implant that
uses a hydrogel to deliver
intravitreal TKIs to disrupt
downstream VEGF signaling

Figure 1 Summary of treatments discussed for neovascular (“wet”) age-related macular degeneration (AMD).
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Figure 2 Summary of treatments discussed for non-neovascular (“dry”) age-related macular degeneration (AMD).

not recommended (36,38).
A few small randomized trials have evaluated
adjunctive steroid administration in eyes resistant
t o a n t i - V E G F m o n o t h e r a p y. D e s p i t e a n a t o m i c a l
improvements in retinal fluid absorption, no benefit
for visual acuity was seen in patients receiving a
dexamethasone implant in conjunction with antiVEGF therapy (aflibercept or ranibizumab) compared
to controls receiving anti-VEGF therapy alone (39).
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However, older literature has shown that triple therapy
consisting of PDT, dexamethasone, and bevacizumab can
improve visual acuity, stabilize vision, and potentially reduce
the number of anti-VEGF injections required (40-42).
Statistical significance failed to be proven due to small
sample sizes, and given the development of new therapies
and efficacy of current anti-VEGF monotherapy, triple
therapy is uncommon for the treatment of nAMD in clinical
settings today.
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Anti-VEGF intravitreal therapies
The first systemically administered anti-VEGF agent
available on the market was bevacizumab (Avastin ®), a
full-length, humanized anti-VEGF-A monoclonal IgG1
antibody that was FDA approved in 2004 for the treatment
of metastatic colon cancer (43). Later that year, pegaptanib
(Macugen®), an anti-VEGF RNA aptamer that selectively
binds VEGF-165 with high affinity, was the first ocular antiVEGF therapy FDA approved for nAMD treatment (44).
Pegaptanib decreased the rate of visual-acuity loss,
progression to blindness, and the number of letters lost by
50% after 1 year of treatment (45). Shortly thereafter, an
open-label, uncontrolled clinical study found that systemic
infusion of bevacizumab was also efficacious for nAMD
treatment (46). Clinicians began using off-label bevacizumab
IVIs which were later shown to improve functional visual
outcomes in nAMD patients (47). The use of pegaptanib
was consequently discontinued by many clinicians due to
the availability of more effective treatments.
The off-label use of bevacizumab was efficacious, but
researchers believed a treatment with a smaller molecular
weight than bevacizumab [149 kilodaltons (kDa)] could
potentially reach the choroid more efficiently. Ranibizumab
(Lucentis®, 48 kDa), a humanized anti-VEGF-A antibody
fragment that utilizes an affinity-matured Fab region
derived from the same parent molecule as bevacizumab (48),
was subsequently developed specifically for intravitreal
nAMD treatment and FDA approved in 2006. Ranibizumab
was the first ocular anti-VEGF drug to significantly
improve visual acuity and prevent vision loss in nAMD
patients after one year of monthly treatment (25).
In 2011, The Comparison of Age-Related Macular
Degeneration Treatment Trials (CATT) found that
intravitreal bevacizumab and ranibizumab treatment had
equivalent effects on functional visual outcomes (49).
Minor differences in visual acuity improvement were seen
between patients receiving as-needed treatments of either
drug compared to those receiving monthly treatments
after both 1 and 2 years (27). That same year, the FDA
approved another intravitreal nAMD treatment: aflibercept
(Eylea®), a chimeric fusion protein consisting of the second
immunoglobulin (Ig) domain of VEGF receptor (R)-1,
third Ig binding domain of VEGFR-2, and Fc region of
human IgG1 (50). Aflibercept uniquely binds all isoforms
of VEGF-A, in addition to VEGF-B, and placental growth
factor (PIGF) which is selectively expressed in pathological
angiogenic tissue (51).
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While ranibizumab and aflibercept have been FDA
approved for wet AMD, off-label bevacizumab remains a
common treatment choice due to its significantly lower cost
and non-inferior clinical efficacy (bevacizumab is 40 times
cheaper than ranibizumab and aflibercept) (52). When
comparing ranibizumab and aflibercept in treatment-naïve
nAMD patients, no significant differences were found
in visual acuity after 1 year of IVI (53). Similar anatomic
response rates for macular thickness and subretinal fluid
have been found between bevacizumab, ranibizumab,
and aflibercept (54). Taken together, the choice of antiVEGF therapy can usually be decided on an individual
basis between providers and patients, with particular
consideration regarding out-of-pocket-cost and treatment
administration frequency.
An ophthalmic formulation of bevacizumab, ONS5010 (Lytenava®), is currently being investigated in the
NORSE 2 Phase III clinical trial (55). The NORSE 1
Phase II trial showed no statistical differences in eyes
treated with intravitreal ONS-5010 compared to eyes
treated with intravitreal ranibizumab in safety measures,
visual acuity, and letter-line improvement after 11 months
of treatment. Results from the Phase III trial are expected
in 2021, and if successful, ONS-5010 will be the first FDAapproved formulation of bevacizumab to be used for retinal
indications.
Brolucizimab is the most recent anti-VEGF therapy to
be FDA approved in 2019. With a molecular weight of only
26 kDa, this humanized, single-chain variable fragment
binds VEGF-A with greater bioavailability than previous
therapies (56). Visual acuity at 2 years was shown to be
non-inferior when administered at every 3 month intervals
as compared to bimonthly aflibercept injections (57).
However, reports of occlusive vasculitis after brolicuzimab
injection have led to apprehension in the ophthalmology
community in adopting its use (58).
Anti-VEGF intravitreal gene therapy
Gene therapy has recently emerged as a viable treatment
method for monogenic hereditable dystrophies and is
undergoing investigation for retinal degenerative diseases
such as AMD. In the latter case, the goal of intravitreal gene
therapy is to offer a long-lasting, single-dose treatment
that has sustained therapeutic effect through creating a
protein biofactory (20). The eye is a particularly good
candidate for gene therapy for several reasons: (I) it is easily
accessible, (II) treatment can be monitored using non-
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Table 1 Summary of pros and cons of different treatment delivery routes used for age-related macular degeneration
Route of administration Advantages

Disadvantages

Intravitreal

Minimally invasive; commonly used; efficient,
in-office procedure

Increased humoral response to intravitreal gene therapy;
requires higher dose to achieve therapeutic effect at the outer
retina or RPE

Subretinal

Direct drug delivery to RPE, which is particularly
useful in gene therapy; greater immune privilege
when compared to intravitreal injection

Requires PPV and creation of a retinotomy; potentially
challenging surgical approach that is not yet commonly used;
longer procedure time; procedure associated complications
including cataract formation and retinal detachment

Suprachoroidal

Does not require creation of a retinotomy; high
bioavailability in the RPE, sclera, and choroid;
avoids PPV-associated complications

Novel surgical approach that is not yet commonly used; longer
procedure time; theoretical increased risk of suprachoroidal
hemorrhage

Topical (eye drops)

Convenient and accessible; non-invasive;
do not require patient to come to physician’s
office

Poor bioavailability in the posterior segment; increased
systemic exposure to the medication

Systemic (oral)
Systemic (intravenous)

Minimal risk of ocular complications

IOP, intraocular pressure; RPE, retinal pigment epithelium; RRD, rhegmatogenous retinal detachment.

invasive technology, such as optical coherence tomography
(OCT), (III) ocular immune privilege reduces the risk
of significant host-immune response, (IV) an effective
therapeutic dose may be achieved with a smaller quantity
of viral vector, and (V) systemic exposure is limited due to
anatomical barriers inherent to the eye (59,60). Luxturna®
(voretigine neparvovec-rzyl) was the first ocular gene
therapy to be FDA approved in 2017 for treatment of Leber
congenital amaurosis type 2 (LCA2) (61), pioneering the era
of gene therapy for inherited and acquired ocular diseases
alike. Luxturna utilizes an adeno-associated virus (AAV)based viral vector, a delivery vehicle shared by many other
ocular gene therapies (62,63), to deliver a functional copy
of the RPE65 gene (64). Several anti-VEGF gene therapy
treatments are also being investigated for both dry AMD and
wet AMD. Table 1 summarizes the different ocular routes of
administration for gene and non-gene therapies for AMD.
ADVM-022 (Adverum Biotechnologies) is a novel,
adeno-associated virus (AAV)-based therapy that utilizes
an AAV2 capsid to deliver cDNA encoding the aflibercept
protein (65). This therapy is currently being investigated in
the ongoing phase I OPTIC trial (66). As of June 2020, 2
cohorts of 6 eyes each have been enrolled in the study and
have received one IVI of ADVM-022 at 6×1011 vg/eye and
2×10 11 vg/eye, respectively. Complications were limited
to inflammation related to the injection. No subject has
required rescue anti-VEGF injection since initial ADVM022 treatment, with visual acuity being maintained and
imaging showing improvements in retinal anatomy across
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all eyes. The efficacy of this treatment is promising, and
further results are underway. However, several challenges
inherent to the intravitreal delivery route exist. Intravitreal
viral vectors are limited in their ability to transduce RPE or
photoreceptor cells, the most common retinal gene therapy
targets, due to the physical barriers imposed by the internal
limiting membrane and retinal layers (67). To overcome
these physical limitations of IVIs, subretinal delivery of
gene therapy has also been evaluated as a delivery route for
ocular gene therapy.
Subretinal (SR) therapies
The SR space offers direct access to the diseased RPE, but
subretinal delivery is significantly more difficult and invasive
when compared to IVIs (68). A protocol recently published
by Davis et al. (69) details the procedure for SR delivery of
gene therapy as follows: (I) surgical preparation, including
vector preparation and injection site planning; (II) pars plana
vitrectomy and induction of a posterior vitreous detachment;
(III) creation of a retinotomy, and optional creation of a prebleb with balanced salt solution, forming a localized retinal
detachment between the RPE and photoreceptor layer; and
(IV) vector injection via a subretinal microcannula into the
bleb. A limitation of this technique is that only relatively
small areas of the retina can be treated at a time. Thus,
multiple retinotomies may be required to treat the desired
retinal surface area. The procedure poses the typical risks of
vitreoretinal surgery, including cataract development, retinal
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detachment, and possible vision loss (69). Additionally,
vector material may reflux into the vitreous through
the injection site and lead to formation of an epiretinal
membrane that can worsen visual outcomes (70). Despite the
challenges associated with SR drug delivery, it is particularly
important in certain inherited retinal disorders to target
the SR space when administering gene or cell therapy. This
method of drug delivery continues to be explored as an
important modality for gene therapies.
Subretinal anti-VEGF gene therapy
A current Phase I/IIa trial using RGX-314 (Regenxbio) has
shown promising results utilizing a novel AAV-8 vector to
subretinally deliver a soluble anti-VEGF Fab protein (71).
Five different doses of RGX-314 (3×10 9, 1×1010, 6×1010,
1.6×1011, and 2.5×1011 genome copies/eye) were evaluated
for safety and efficacy in 42 eyes previously treated
with nAMD therapy. As of August 2020, no immune or
inflammatory responses beyond what is normally expected
post-retinal surgery were observed, and all confirmed
adverse effects during the trial have not been drug-related.
Cohorts 3 (6×1010 genome copies/eye), 4 (1.6×1011 genome
copies/eye), and 5 (2.5×1011 genome copies/eye) have shown
the best results in the study thus far, with a 62.2%, 61.3%,
and 84.5% decrease seen in annual anti-VEGF injection
rates respectively.
Suprachoroidal approach
The suprachoroidal space (SCS) is another attractive
space for drug delivery applied in AMD and other retinal
degenerations. It has been evaluated as an effective site for
drug delivery using various molecular and protein-based
therapies (72-77). Due to its close proximity to the retina
and RPE, the SCS also offers the potential for low drug
doses with high bioavailability in the posterior segment (78).
Drug delivery into the SCS also avoids the risks associated
with retinal surgeries while potentially offering similar
immune privilege to SR drug delivery.
Recent clinical trials have shown successful distribution
of ocular therapies to the SR space via SCS delivery (79).
Three different SCS delivery methods have been described
in the literature thus far. Freehand injection using a
standard hypodermic needle is the simplest approach for
drug delivery to the SCS: the surgeon advances the needle
through the sclera and into the SCS at a tangential angle,
and injects the drug which diffuses within the SCS (80). This
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method has been evaluated in preclinical models but the
difficulty in reproducible SCS access precludes clinical use.
Alternatively, a much shorter, 700-μm microneedle has been
tested for transscleral injection in in-vivo animal models (81)
and involves a protocol similar to IVI. This technique is
planned to be incorporated in clinical trials evaluating
suprachoroidal anti-VEGF gene therapy for nAMD. Lastly,
a flexible, tunneled microcatheter has been used to allow
suprachoroidal and suprachoroidal-to-subretinal delivery to
the posterior pole. The surgeon creates a limbal conjunctival
peritomy followed by a radial scleral cut down, allowing the
catheter to enter the SCS and be guided to its target site
using indirect ophthalmoscopy (82). Preclinical studies have
shown an acceptable safety profile for these SCS approaches
without severe adverse events such as suprachoroidal
hemorrhage (82-86). Clinical trials are also planned using
tunneled microcatheters for suprachoroidal-to-subretinal
gene therapy in AMD with GA.
Suprachoroidal anti-VEGF therapy
Preclinical trials have evaluated gene therapy delivery into
the SCS using animal models and have suggested diffuse
distribution in the RPE 2 weeks following injection (87).
A single injection of RGX-314, the same AAV8 vector
expressing anti-VEGF that was described in a previous
section, successfully suppressed CNV in rodent eyes
within 2 weeks of administration, and maintained similar
findings on evaluation 7 weeks after treatment (80).
Additionally, no differences in anti-VEGF levels in the
retina were found between therapy delivered in the SR
space versus the SCS.
In September 2020, Ocular Therapeutix® announced
the development of OTX-AFS, an extended-release
suprachoroidal formulation of aflibercept, following
promising, preliminary results in their phase I trial on
OTX-TKI (described in the section on hydrogels) (88). A
protocol for a phase I trial is scheduled to be released soon.
Additionally, the FDA recently approved initiation of a
phase I/IIa clinical trial evaluating suprachoroidal delivery
of CLS-AX (Clearside Biomedical), an injectable suspension
containing axitinib (89). Axitinib is a tyrosine kinase
inhibitor (TKI) that disrupts downstream VEGF signaling,
and is currently approved for treatment of renal cell cancer.
Preclinical data in animal models has shown CLS-AX to
be durable in the SCS, well-tolerated, and successful in
preventing further CNV (90). This trial is set to begin
enrolling within the coming months.
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Nanotechnology and other drug delivery systems
Advancements in nanotechnology and biomaterials have led
to the development of microscopic drug delivery systems
(DDSs), including hydrogels, microparticles, nanoparticles,
implants, and liposomes (91,92). The use of DDSs for
ocular therapy offers many advantages that make them an
attractive alternative to the current mainstay treatment
of IVIs. These include improved retinal penetration and
tapered release of highly concentrated drug therapies (93),
which both serve to reduce the treatment and surveillance
burden. However, loading DDSs with anti-VEGF molecules
and other protein-based therapies is more complicated from
a pharmacological standpoint due to their fragile tertiary
and quaternary structures (94). The technique involved in
delivering various DDSs will be discussed in each subsection
when applicable.
Port delivery systems (PDS)
PDS has shown promise for long-lasting delivery of antiVEGF medication that may decrease IVI treatment burden
for nAMD. The PDS implant is a novel drug delivery
system that acts as a depot and continuously delivers a
therapeutic agent (i.e., ranibizumab) into the vitreous
cavity over extended periods of time (95). Prior to surgical
insertion, local anesthesia is administered (96). Scleral
implantation is accomplished via conjunctival peritomy,
scleral dissection using a 3.2 mm blade, 532 nm laser
ablation of the exposed pars plana, and insertion of the
self-retaining device into the scleral opening (96). Once
implanted, the drug passively diffuses from the release
control element into the vitreous, offering sustained-release
until emptied. Similar to IVIs, the PDS can be refilled
in-office using a small needle to inject new fluid into the
implant.
Recent results from the LADDER phase II trial of a
ranibizumab PDS show similar functional and anatomical
visual outcomes as monthly intravitreal ranibizumab (95). No
significant differences were found between time to first refill
across the 40-mg/mL, and 100-mg/mL PDS dosage-arms,
with median refill times ranging from 13 to 15 months. The
10-mg/mL arm had a median refill time of 8.7 months, which
is still a significantly lower treatment burden than monthly
IVIs (95). As expected, higher rates of adverse effects were
noted in the PDS arm when compared to IVI, including
vitreous hemorrhage, nausea, and headache. However, these
events were not severe and did not cause significant visual
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acuity deficits (97). Endophthalmitis was also a complication
of the technique.
The phase III ARCHWAY study is currently underway
and is assessing safety and non-inferiority of 24-week PDS
dosing to monthly IVI delivery of ranibizumab. Initial
results have successfully proven non-inferiority, with a
0.5 letter gain in the monthly injection arm to a 0.2 letter
gain in the PDS arm, and only 2% of subjects requiring
a medication refill in the PDS arm prior to the scheduled
24-week refill (98).
Hydrogels
To overcome the surgical risks associated with PDS,
injectable hydrogels are being explored as potential extendedrelease DDSs for ocular drug therapy (14). Hydrogels are
water-soluble DDSs that form three-dimensional, crosslinked polymer networks (99). They offer varying levels
of porosity, distensibility, and mechanical resistance, and
these features can be modulated through natural, synthetic,
or hybrid polymers (14). When incorporating therapeutic
agents into the polymer network, each gel’s unique crosslinking properties must be accounted for to ensure bioactivity
upon arrival to the target site (100-103).
To date, only one ocular hydrogel DDS has reached clinical
trials. OTX-TKI (Ocular Therapeutix) is an injectable,
biodegradable implant that utilizes a hydrogel to deliver
intravitreal TKIs to disrupt downstream VEGF signaling
(104,105). Once implanted into the vitreous, OTX-TKI
offers sustained drug-release for up to 6–7 months (105). Preclinical in vitro studies in Dutch belted rabbits demonstrated
successful delivery and maintenance of high OVX-TKI
concentrations in the vitreous using this therapy (106).
Precise information regarding the structural design of
OTX-TKI is currently unavailable, though a presentation
regarding this novel technology given by Ocular Therapeutix
in October 2020 advertises a polyethylene glycol hydrogel
delivery platform (107). The current phase I trial has fully
enrolled two cohorts using 200 µg, and 400 µg doses,
respectively, and a third cohort is in the process of being
enrolled to compare 600 to 400 µg + anti-VEGF induction
injection. According to the most recent presentation, subjects
in the first two cohorts have demonstrated a favorable safety
profile. In cohort 2 (400 µg), one patient demonstrated
treatment durability of 9 months, and a few subjects showed
decreased retinal fluid on OCT by 2 months. Comprehensive
results are still underway, and will be closely followed.
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Polymers
The brimonidine DDS (Allergan) is a biodegradable
intravitreal implant made from a polymer matrix (14). It
is loaded with brimonidine tartrate, a selective alpha-2
adrenergic receptor agonist, and is currently used to treat
glaucoma. Brimonidine has been shown to reduce oxidative
stress in the RPE (108) and has a neuroprotective effect in
in vitro models of retinal degeneration (109). Results from
the recent phase II clinical trial showed the brimonidine
DDS to be a safe and effective treatment of GA secondary
to dry AMD (110). When compared to sham groups, eyes
treated with 132 and 264 µg of brimonidine via DDS had
significantly less growth in geographic atrophy lesion size. A
phase III trial is currently in the process of being developed.
Small-interfering RNA (siRNA)
siRNA is a class of double-stranded RNA molecules that
regulates gene expression via RNA interference (RNAi) (111),
a biological process that inhibits gene expression via
degradation of complementary messenger RNA (112).
siRNA-based therapies have recently emerged as promising
treatments for nAMD, offering translational modulation
of pathological protein production, convenient intravitreal
delivery, the potential to elicit a pan-retinal effect, and a
high level of specificity (113,114). A few ocular drugs in
this class have been developed to target the main pathway
involved in the pathogenesis of AMD: the pro-angiogenic
VEGF pathway (115).
Bevasirinib, an anti-angiogenic siRNA therapeutic
designed to silence the VEGF gene using an RNAi
mechanism, was the first intravitreal siRNA therapy
developed for nAMD (115,116). Despite being successful
in both in vitro and in vivo models (117), the phase III
trial was discontinued in 2009 due to failure to show
bevasirinib injections at 8 to 12 week intervals (after initial
pre-treatment with 3 ranibizumab injections) to be more
effective than monthly ranibizumab injections (118,119).
AGN211745 (also known as siRNA-027) is another antiangiogenic siRNA that utilized RNAi technology to
target VEGFR-1 in patients with CNV (120). Similar to
bevasirinib, development of AGN211745 was halted in 2009
following a phase II trial due to insignificant improvements
in visual acuity (121).
Recent advances in siRNA therapy include the FDA
approval of ONPATTRO® in 2018 and GIVLAARITM
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in 2019 for use in hereditary transthyretin-mediated
amyloidosis and acute hepatic porphyria, respectively (122).
RNA-based drug therapies utilizing RNAi mechanisms are
thus effective treatments, and further research is warranted
for future AMD therapies of this nature.
Designed ankyrin repeat proteins
Ankyrin repeats are naturally occurring amino acid motifs
that perform various cellular functions, including cell-cell
signaling, cell cycle regulation, and transcription (123).
These repeats serve as high-affinity scaffolding domains for
high-specificity interactions with target receptors (124,125)
and are great candidates for drug delivery due to their
stable thermodynamic properties (126). Designed ankyrin
repeat domains (DARPins) were engineered to mimic
these protein structures. This platform was first introduced
in ocular therapeutics as abicipar pegol, a high-affinity
VEGF-A binder (127) delivered via IVI with up to 5.5 times
more concentrated dosages than ranibizumab (128).
The recent phase II REACH trial compared functional
and anatomical visual outcomes in naive nAMD patients
randomized into three arms: 0.5 mg IVI of ranibizumab,
1 mg IVI of abicipar, or 2 mg IVI of abicipar (128). Results
were promising and showed similar best corrected visual
acuity and reduction in central retinal thickness across all
arms. This prompted the phase III SEQUOIA and CEDAR
clinical trials to assess the efficacy and safety of abicipar.
Non-inferiority was established when comparing abicipar
to ranibizumab, and treatment burden was shown to be
lower with 8-week and 12-week abicipar regimens (129).
However, intraocular inflammation (IOI) rates were
relatively high after administration of abicipar, affecting
10.4% of patients in phase II trials and 15.3% of patients
in phase III trials (130). Although reported IOI rates for
current intravitreal anti-VEGF range from 0.3–14.3%
(131-135), the FDA did not approve abicipar for clinical
use in nAMD patients due to the unfavorable risk-benefit
ratio. Despite the shortcomings of abicipar’s safety profile,
DARPins are promising, advanced DDSs that should
continue to be explored as potential AMD treatments.
Oral therapy
Oral therapy is perhaps the most common and convenient
route for systemic drug administration. Oral drug dosages
can be easily adjusted, self-administered, is non-invasive,
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and has the potential for solid formulations to have a long
shelf-life (136). For patients with systemic diseases and
concomitant ocular manifestations, oral administration
is effective and reduces patients’ total drug intake (137).
However, for patients with localized eye disease, oral
dosages are not as appealing due to the many ocular
barriers preventing efficient drug delivery to the posterior
segment. Higher dosages or greater frequency of oral
drug administration may thus be required to achieve the
desired therapeutic effect, posing a significant risk of drug
toxicity (138). For this reason, X-82, an oral anti-VEGF/
PDGF formulation designed for nAMD treatment, failed
to demonstrate safety and tolerability in phase II trials
despite promising results in previous trials (139). Oral drug
administration has also been shown to produce an ocular
bioavailability of only 2% (140), making this route of drug
delivery inefficient for AMD and other localized ocular
diseases.
Age-Related Eye Disease Studies (AREDS) 1 and 2
were large, multicenter phase III trials that analyzed the
effects of nutritional supplements and dietary modifications
on AMD progression (141,142). Oral supplementation of
specific combinations of vitamins (C and E), carotenoids
(lutein and zeaxanthin), and minerals (zinc and copper) was
shown to decrease the risk of progression to late stages of
AMD and GA (143,144). Adherence to a Mediterranean
dietary pattern with high intake of omega-3 fatty acids
decreased risk of progression to GA as well (145). Due to
minimal risks associated with these supplements and dietary
changes and the potential for disease-sparing benefits, some
ophthalmologists recommend these to patients diagnosed
with early stages of AMD.
Several other oral pharmaceuticals are being investigated
in clinical trials for their potential therapeutic effects
in patients with GA. Oral doxycycline (Oracea ® ) is
currently being investigated in a phase III trial for its antiinflammatory effects and potential to reduce the rate of
GA spread (146). Metformin, a commonly prescribed drug
for type II diabetes mellitus, has been noted for its role
in preventing AMD development (147,148). It activates
retinal 5' adenosine monophosphate-activated protein
kinase (AMPK) and glucose metabolism, and these two
mechanisms have been shown to be protective of the
RPE and photoreceptor layers in rodent models (149). An
ongoing phase II trial is evaluating the safety and efficacy of
metformin for progression of GA in non-diabetic patients,
and results are expected in October 2021 (150).
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Dry AMD therapies
To date, there are no FDA approved therapies for dry AMD
progression or GA despite being common precursors to
vision loss. The total area of GA grows geometrically over
time, and mean time to central involvement is 2.5 years.
Bilateral eye involvement, on average, occurs 7 years after
initial GA diagnosis (151,152). GA development is not
exclusive to dry AMD, as studies have shown up to 17–18%
of nAMD patients receiving anti-VEGF treatment develop
GA within 2 years (153,154). These numbers translate
to devastating effects on patients’ vision and quality of
life, and the prevalence of advanced AMD is projected to
double by 2040 (1). Thus, treatments for prevention of
GA progression are becoming more crucial as the global
population continue to age. The complement cascade has
been implicated as a central factor in the multifactorial
pathogenesis of GA (11), and therapeutics that target the
inhibition of various complement factors are currently in
trials.
Complement cascade inhibitors
C5 is an effector molecule produced by all three pathways of
the complement cascade and plays a key role in forming the
membrane attack complex (MAC) (155). Chronic activation
of MAC may lead to death of the RPE, and therapies
that selectively inhibit C5 may mitigate this pathogenic
complement dysregulation seen in advanced forms of AMD
(155,156). In 2007, eculizumab, a monoclonal human
antibody to C5, was first FDA approved for treatment of
paroxysmal nocturnal hemoglobinuria. By blocking C5,
eculizumab prevents downstream activation of the terminal
complement system and inhibits formation of the MAC.
It was thus thought to be a potential systemic treatment
for GA, and was investigated in the COMPLETE phase II
study. Thirty patients were randomized into one of three
intravenous treatment groups: low dose eculizumab (600 mg
for 4 weeks, then 900 mg every other week for 20 weeks),
high dose eculizumab (900 mg for 4 weeks, then 1,200 mg
every other week for 20 weeks), or placebo (157). At both
26 weeks and 52 weeks of follow-up, eculizumab failed to
decrease GA lesion progression when compared to placebo
(P=0.96 and P=0.93, respectively). However, no subjects
progressed to wet AMD, and thus a different study endpoint
with longer follow-up may be warranted to determine its
efficacy in this regard.
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Avacincaptad pegol (Zimura®), a pegylated RNA aptamer
delivered via IVI, is a novel C5-inhibitor currently in phase
III trials for treatment of GA (158). A total of 286 subjects
with GA secondary to AMD were randomized into one
of three avacincaptad dosage groups during the first part
of the phase II trial: 1 mg, 2 mg, and sham (159). The
second part of this trial randomized 209 subjects into 2 mg
avacincaptad, 4 mg avacincaptad, and sham cohorts. The
results from this trial showed that avacincaptad reduced
the rate of atrophic area spread by 27.4% and 27.8% in the
2 and 4 mg treatment groups respectively (159), had a 0%
incidence rate of endophthalmitis, and a favorable safety
profile with no drug-related adverse events. Ongoing phase
III trials are aiming to confirm the efficacy of avacincaptad,
and if successful, will be the first treatment option available
to individuals with GA.
C3 is an upstream component of C5 in the complement
cascade, and marks the convergence of the three
complement pathways that may ultimately lead to cell lysis
and inflammation (160). C3 plays a key role in complement
cascade amplification, particularly through the alternative
pathway (161,162), and its breakdown products are markedly
elevated in serum plasma of patients with GA (163).
Pegcetacoplan (APL-2) was the first complement inhibitor
to enter clinical trials for treatment of dry AMD and GA.
It is a synthetic peptide embedded in a linear, polyethylene
glycol polymer, and its potent inhibition of C3 offers
the potential for broad anti-inflammatory effects (164).
Phase II trials showed a 29% reduction in the GA growth
rate during a 12-month period in patients receiving monthly
intravitreal pegcetacoplan, and a 20% reduction in patients
receiving treatment every other month when compared to
sham injections (165). 1.2% of patients enrolled in the trial
developed endophthalmitis. The phase III trial is currently
underway and has enrolled 1, 259 patients. The primary
aims are to further evaluate APL-2’s efficacy in reducing
rates of GA spread and its safety profile. Results of this
phase III trial are expected in 2021.
Factor D is an important activator of C3 convertase,
and acts as the rate-limiting enzyme of the alternative
pathway (166,167). It was thus thought to be a viable
therapeutic target for treatment of dry AMD, leading to
the development of lampalizumab, an antigen-binding
fragment against Factor D. In a phase II trial, lampalizumab
IVI successfully reduced GA lesion growth by 20% in an
18-month period when compared to sham (168). However,
Chroma and Spectri, two identical phase III trials, failed to
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show significant differences in slowing GA progression over
48 weeks with every 4 or 6 week lampalizumab injection.
These trials found lesions to enlarge by an average of
2 mm2 each year, consistent with the natural rate of GA
progression described in the literature (13), and were thus
suspended in September 2017 (169).
Other intravitreal therapies
Gene therapy is also being explored to target components
of the complement pathway. CD59 is a natural inhibitor of
MAC (170), and is currently being studied as a therapeutic
target for both dry and wet AMD. AAVCAGsCD59
(HMR59) is an IVI that uses an AAV2 vector to deliver
soluble CD59 gene product to the RPE (171). Phase I trials
evaluating HMR59 are currently underway for both forms of
AMD. Another gene therapy being investigated for dry AMD
is subretinal GT005, which uses an AAV2 vector to code for
complement factor I (CFI) (172). CFI is a serum protease
that can inhibit the entire complement cascade (173),
and pre-clinical trials in rodent models have shown dosedependent decreases in complement activation and CNV
when treated with GT005 (172). There have yet to be
any safety concerns in the ongoing phase I/II trials in the
United Kingdom, and results are forthcoming.
High-temperature requirement A serine peptidase
1 (HtrA1) has been implicated in the pathogenesis of
geographic atrophy, inducing breakdown of the extracellular
matrix protein and degeneration of photoreceptors and
RPE. Locus variations of the ARMS2/HTRA1 gene have
been implicated to increase risk of dry AMD development
and progression (174). FHTR2163 is an IgG1 monoclonal
antibody targeting HtrA1 administered as intravitreal
injections every 4 to 8 weeks. The phase I open-label trial
met safety criteria and a phase II clinical trial (GALLEGO)
is currently enrolling patients to determine its efficacy in
reducing GA lesion progression and safety profile (175).
Eye drop therapies
Eye drop therapies are commonly used for treatment of
anterior segment pathologies. Topical drug delivery to the
posterior segment is limited due to inherent ocular barriers,
including its many structural layers, dynamic blood flow,
and presence of efflux pumps (140). Despite this challenge,
eye drop formulations continue to be explored due to their
convenience and ease of use. OT-551 is a small, lipophilic
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molecule with antioxidant properties (176). Due to its
ability to penetrate membranes and protective properties
of antioxidants, OT-511 was investigated in a phase II
trial in 2010 for its efficacy in reducing GA progression
(176,177). Ten patients were treated with topical 0.45%
OT-551 monocularly for 2 years in a randomized fashion;
the fellow eye served as a control. Though the primary
outcome of reducing the GA lesion progression failed to
be met, a decrease in visual acuity was significantly lower
in the treatment eye than in the fellow eye (176). However,
larger studies failed to replicate this effect and OT-551 did
not progress to larger clinical trials. MC-1101, a vasodilator
with antioxidant and anti-inflammatory properties,
successfully demonstrated safety and tolerability in a phase
Ib trial (178). Phase II/III trials are currently underway to
investigate its efficacy in maintaining visual function (179).
Stem cell therapies
Stem cells are promising vehicles for tissue regeneration
and if successful, may revolutionize the prognosis of
degenerative diseases. Research on ocular stem cell therapy
has involved cells from various cell lines in both pre-clinical
and clinical trials, including human embryonic stem cells
(hESCs) (180-182), induced pluripotent cells (iPSCs) (183),
and human umbilical tissue-derived cells (hUTCs) (79). The
intended effects of ocular cell therapy depend on the site of
delivery and type of cell. In some cases, the goal is for cells
to secrete a trophic, immunomodulatory or neuroprotective
factor while in others the cells directly replace damaged or
degenerated RPE or photoreceptors (184).
A phase I trial involving 2 patients successfully delivered
an RPE patch derived from hESCs, with significant visual
improvements of 21 and 29 letter-line after 12 months (180).
Another phase I/IIa trial enrolled 16 subjects with
advanced atrophic AMD, and demonstrated the feasibility
of subretinal implantation of an hESC-derived RPE
monolayer (181). The National Eye Institute is currently
launching a phase I/IIa trial of 12 subjects with GA to
evaluate the safety of transplanting an RPE monolayer from
autologous iPSCs (183).
In human clinical trials, the use of hESC and iPSCderived therapies is still in its early stages, with under
100 patients undergoing transplantation thus far (185).
Limitations of stem cell therapy include the risk of
oncogenicity, need for more efficient cell-line generation,
and lack of knowledge regarding the translation of results
seen in animal studies to human subjects. The journey
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ahead for stem cell therapy is exciting, but many challenges
must be overcome before it enters clinical use.
Conclusions
The introduction of anti-VEGF therapies as the gold
standard for nAMD has been associated with a 46–50%
decrease in vision loss attributable to nAMD (186,187).
However, standard-of-care monthly intravitreal dosing
is a burdensome treatment regimen for many patients.
Gene therapy and stem cell therapy have shown promising
early results in clinical trials, as have various PDSs and
nanotechnology therapies. They offer the potential for an
expanded range of therapeutic opportunities for patients
with nAMD and/or GA. Aside from oral vitamin/mineral
supplementation, no current treatments exist to ameliorate
progression to advanced AMD. Significant unresolved gaps
in knowledge exist in both disease-modifying drug targets
and drug/delivery systems which are an important area of
study. A critical need for treatment of dry AMD and GA
remains unmet and is a driving force for the development of
new drug therapies and delivery options in AMD research.
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